rs786204491
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PVS1PP5_Very_Strong
The NM_004004.6(GJB2):c.290_291insA(p.Tyr97Ter) variant causes a stop gained, frameshift change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000013 in 1,613,684 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Pathogenic (★★).
Frequency
Genomes: 𝑓 0.000020 ( 0 hom., cov: 33)
Exomes 𝑓: 0.000012 ( 0 hom. )
Consequence
GJB2
NM_004004.6 stop_gained, frameshift
NM_004004.6 stop_gained, frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 7.97
Genes affected
GJB2 (HGNC:4284): (gap junction protein beta 2) This gene encodes a member of the gap junction protein family. The gap junctions were first characterized by electron microscopy as regionally specialized structures on plasma membranes of contacting adherent cells. These structures were shown to consist of cell-to-cell channels that facilitate the transfer of ions and small molecules between cells. The gap junction proteins, also known as connexins, purified from fractions of enriched gap junctions from different tissues differ. According to sequence similarities at the nucleotide and amino acid levels, the gap junction proteins are divided into two categories, alpha and beta. Mutations in this gene are responsible for as much as 50% of pre-lingual, recessive deafness. [provided by RefSeq, Oct 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 16 ACMG points.
PVS1
Loss of function variant, product does not undergo nonsense mediated mRNA decay. Variant is located in the 3'-most exon, not predicted to undergo nonsense mediated mRNA decay. There are 31 pathogenic variants in the truncated region.
PP5
Variant 13-20189291-G-GT is Pathogenic according to our data. Variant chr13-20189291-G-GT is described in ClinVar as [Pathogenic]. Clinvar id is 188821.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GJB2 | NM_004004.6 | c.290_291insA | p.Tyr97Ter | stop_gained, frameshift_variant | 2/2 | ENST00000382848.5 | NP_003995.2 | |
GJB2 | XM_011535049.3 | c.290_291insA | p.Tyr97Ter | stop_gained, frameshift_variant | 2/2 | XP_011533351.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GJB2 | ENST00000382848.5 | c.290_291insA | p.Tyr97Ter | stop_gained, frameshift_variant | 2/2 | 1 | NM_004004.6 | ENSP00000372299 | P1 | |
GJB2 | ENST00000382844.2 | c.290_291insA | p.Tyr97Ter | stop_gained, frameshift_variant | 1/1 | ENSP00000372295 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152082Hom.: 0 Cov.: 33
GnomAD3 genomes
AF:
AC:
3
AN:
152082
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000120 AC: 3AN: 251002Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135676
GnomAD3 exomes
AF:
AC:
3
AN:
251002
Hom.:
AF XY:
AC XY:
0
AN XY:
135676
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000123 AC: 18AN: 1461602Hom.: 0 Cov.: 33 AF XY: 0.00000825 AC XY: 6AN XY: 727114
GnomAD4 exome
AF:
AC:
18
AN:
1461602
Hom.:
Cov.:
33
AF XY:
AC XY:
6
AN XY:
727114
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152082Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74286
GnomAD4 genome
AF:
AC:
3
AN:
152082
Hom.:
Cov.:
33
AF XY:
AC XY:
1
AN XY:
74286
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:9
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:4
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Oct 28, 2020 | Nonsense variant in the C-terminus predicted to result in protein truncation, as the last 130 amino acids are lost, and other loss-of-function variants have been reported downstream in the Human Gene Mutation Database (Stenson et al., 2014); This variant is associated with the following publications: (PMID: 31589614, 32747562, 15070423, 28405014, 24529908, 19371219, 17935238, 25560255, 11584050, 22695344, 22000900, 25012701, 15488970, 24039984) - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Dec 16, 2022 | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 188821). This premature translational stop signal has been observed in individual(s) with autosomal recessive non-syndromic hearing loss (PMID: 11584050, 15070423, 19371219, 22695344). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. This variant is present in population databases (rs786204491, gnomAD 0.003%). This sequence change creates a premature translational stop signal (p.Tyr97*) in the GJB2 gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 130 amino acid(s) of the GJB2 protein. - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Medical Genetics and Applied Genomics, University Hospital Tübingen | Oct 23, 2020 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Knight Diagnostic Laboratories, Oregon Health and Sciences University | Oct 04, 2019 | - - |
Autosomal recessive nonsyndromic hearing loss 1A Pathogenic:3
Pathogenic, criteria provided, single submitter | clinical testing | Genomic Diagnostic Laboratory, Division of Genomic Diagnostics, Children's Hospital of Philadelphia | May 09, 2017 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Counsyl | Feb 28, 2018 | - - |
Pathogenic, no assertion criteria provided | clinical testing | Natera, Inc. | Aug 13, 2020 | - - |
Inborn genetic diseases Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Sep 25, 2023 | The c.290dupA (p.Y97*) alteration, located in exon 2 (coding exon 1) of the GJB2 gene, consists of a duplication of A at position 290. This changes the amino acid from an aspartic acid (D) to a stop codon at amino acid position 97. Premature stop codons are typically deleterious in nature; however, because GJB2 is a single-exon gene this alteration is not expected to trigger nonsense-mediated mRNA decay and a truncated protein could still be expressed (Maquat, 2004). This alteration removes the last 130 amino acids of the protein and the exact functional impact of these amino acids is unknown at this time. _x000D_ _x000D_ _x000D_ _x000D_ for autosomal recessive GJB2-related non-syndromic hearing loss; however, its clinical significance for autosomal dominant GJB2-related non-syndromic hearing loss and autosomal dominant GJB2-related syndromic hearing loss with ectodermal involvement is uncertain._x000D_ _x000D_ _x000D_ _x000D_ Manually add references to AVA4 alteration page for Maquat 2004:_x000D_ _x000D_ _x000D_ 15040442 Based on data from gnomAD, this allele has an overall frequency of 0.001% (4/282386) total alleles studied. The highest observed frequency was 0.003% (4/128904) of European (non-Finnish) alleles. This variant has been identified in the homozygous state or in trans with another GJB2 pathogenic variant in multiple individuals with clinical features of GJB2-related non-syndromic hearing loss (Mustapha, 2001; Abbaspour Rodbaneh, 2021; Bonyadi, 2014). Based on the available evidence, this alteration is classified as pathogenic. - |
Autosomal dominant keratitis-ichthyosis-hearing loss syndrome;C0265964:Mutilating keratoderma;C0266004:Knuckle pads, deafness AND leukonychia syndrome;C1835672:Palmoplantar keratoderma-deafness syndrome;C1844678:X-linked mixed hearing loss with perilymphatic gusher;C1865234:Ichthyosis, hystrix-like, with hearing loss;C2673759:Autosomal recessive nonsyndromic hearing loss 1A;C2675750:Autosomal dominant nonsyndromic hearing loss 3A Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Mar 29, 2022 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at